EMA

Workshop on the clinical investigation of new medicines for the treatment of multiple sclerosis

European Medicines Agency, London, UK, 17/10/2013 - 17/10/2013

Summary: The main goal of the workshop is to make sure that in the revision of the multiple-sclerosis guideline, the European Medicines Agency can take the most up-to-date, state-of-the-art scientific developments in multiple sclerosis into consideration, as well as the positions of experts in the field on the main topics in the guideline.

For more details see:

European Medicines Agency

The SLCMSR has been shortlisted as a potential contractor of the EMA for Lots 1,2,3 and 4.
Valid until 02. April 2015

1-Comparative reviews of drug utilisation patterns
2-Observational studies (electronic healthcare and other databases)
3-Observational safety or benefit:risk studies (primary data collection)
4-Systematic reviews or meta-analysis